Dupixent® (dupilumab) late-breaking data at aad show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

More than twice as many patients on dupixent achieved clear or almost clear skin compared to placebo at 16 weeks

REGN Ratings Summary

REGN Quant Ranking